Rezpegaldesleukin not checked

Nektar Therapeutics · NKTR-358 · LY3471851

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
13 in total · 4 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Pharmaceutical form: Injection solution Route of administration: subcutaneous”In the company’s words, NCT07690371 on ClinicalTrials.gov
Tested for
Moderate-to-Severe Atopic Dermatitis (2 trials), Moderate to Severe Atopic Dermatitis
Main trialPhase 3
“This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.”In the company’s words, NCT07690371 on ClinicalTrials.gov
Other names
REZPEG · NKTR-358 · LY3471851

Other drugs for Moderate-to-Severe Atopic Dermatitis

All 90 drugs for Moderate-to-Severe Atopic Dermatitis

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials13

TrialPhaseCompletesWhat it tests
Phase 3Recruiting May 2028 A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Phase 3Recruiting Jun 2028 A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Phase 2Active, not recruiting 6 May 2025 A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Phase 2Terminated 9 Aug 2022 A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Phase 2Completed 10 Jan 2023 A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
Phase 2Completed 26 Nov 2025 A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
Phase 1Completed 20 Jan 2019 A Study of NKTR-358 (LY3471851) in Healthy Participants
Phase 1Completed 29 Aug 2019 A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)
Phase 1Completed 6 Mar 2020 A Study of LY3471851 in Healthy Participants
Phase 1Completed 21 Jul 2021 A Study of LY3471851 in Participants With Psoriasis
Phase 1Completed 24 Jun 2022 A Study of LY3471851 in Participants With Eczema
Phase 1Completed 6 Jul 2022 A Single-Dose Study of LY3471851 in Healthy Participants
Phase 1Completed 23 Feb 2023 A Phase I Study of LY3471851 in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Rezpegaldesleukin

Following is part of Solo: you see every change to Rezpegaldesleukin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in